Immunovant (IMVT) stock

Autoimmune disease products , market cap $6.1B

Autoimmune disease products

Market cap $6.1B

$28.41

-2.61%

As of Monday's close · Live for Pro members at the open

Why is IMVT down?

Down 12% from Oct 5 to Oct 30 while the S&P 500 fell 3%.

Immunovant fell 12% from Oct 5 to Oct 30 while biotech stocks fell a median 4%: it trailed its group by 8 points.

No company filing or news in our sources from Oct 5 to Oct 30.

Sources: Price history, Oct 30, 2026

Tell me next time IMVT moves

Free account, no card. An optional alert when IMVT moves or its score changes.

Or see it live, free until Wednesday morning. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

-6

Poor

In its industry

#235of 291

Biotech

Checks firing

0of 14

Trending up

From 52-week high

-37.5%

Below the 200-day

IMVT's Quality Score was unchanged on Mon, Nov 2, at -6.

Follow IMVT's trial news. Pro members can get an alert when Immunovant files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IMVT files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$798M, about 7 quarters at the last year's spendingOn Jun 30

Key facts on IMVT

Key facts on IMVT
Holding it back	A $538M loss wider than $447M a year earlier
Latest filing	10-Q, Aug 6 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind IMVT's -6, free with an account →2 more reasons behind IMVT's -6, for Pro members.

IMVT in the news

ReportReports Mon Nov 9, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 4 of its last 4 reports, +12.2% on average. Past reports ›

Cash$798M, about 7 quarters at the last year's spendingOn Jun 30

IMVT catalysts

Coming up

After its last 4 reports it closed +12.2% on average, higher 4 of 4 times.

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for IMVT, and how long its cash lasts

Its trials

A trial underway: Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPhase 3 · Recruiting · 231 people · main data estimated Dec 2027 · NCT07039916

7 more trials, 29 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 7 quarters

$798M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CFO Tiago Girao sold 6,606 shares on Oct 28. 36 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Eric Venker buys or sells

For Pro members: every trade, and Eric Venker’s 5 filings and quotes.

Get an alert when IMVT files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why IMVT scores -6

Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means

-6 is below -5, off the left end of the scale.

−2Long-term trend below a falling 200-⁠day average, down over two years
−1Profit A loss of $538M over the last four quarters, more than the $447M lost a year earlier, from the SEC filingsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades subtracts

No effect today: Chart checks, Run-up, Size, Growth, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on IMVT and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:36 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IMVT and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Nothing is firing on IMVT right now

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IMVT, and all 14 on every stock.Get in free →

IMVT RSI today: 36.0, below its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1436.0
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 7 sessions ago.
50-day average$34.24
The price is 17.0% below it.
200-day average$32.05
The price is 11.4% below it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Nov 3, 2025.
ADX 1435.4
25 or more, with +DI below -DI.
Support$26.27
Swing low from Oct 16, 7.5% below the price.
Resistance$29.25
Swing high from Feb 25, 3.0% above the price.
52-week high$45.42
From Aug 19, 59.9% above the price.
52-week low$21.43
From Nov 10, 2025, 24.6% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $26.37 to $31.73.
Volume0.9x
Against its 20-day average, for the time of day.

The deep dive on IMVT

What it does and how it makes money2 findingsFor Pro members2 findings on what IMVT does and how it makes money, for Pro members
Where it stands2 findings1 offering of shares or notes since Dec 2025.SEC filing · Dec 12, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades IMVT, for Pro members
Against its closest peers4 peersShare count against a year before: IMVT +20%, PCVX +6.2%, DNLI +9.3%, SRRK +16%.

5 more findings on IMVT, each with its source, for Pro membersGet in free →

How IMVT ranks in Biotech

IMVT is #235 of 291 by Quality Score.

How IMVT ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	IMTXImmatics		Open for its score
	IMUXImmunic		Open for its score
	INBXInhibrx Biosciences		Open for its score
	INCYIncyte		Open for its score
235	IMVTImmunovant	0/14	-6

Share count against a year before: IMVT +20%, PCVX +6.2%, DNLI +9.3%, SRRK +16%.

When does IMVT report earnings, and what happens after?

Reports Mon Nov 9, before the open (in 7 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+12.4%+35.3%+1.2%

Feb 6May 20Aug 6

Reported	When	Gap	Reaction	5 sessions
Aug 6, 2026Before open	Before open	-3.3%	+1.2%	+8.4%
May 20, 2026Before open	Before open	+15.8%	+35.3%	+27.1%
Feb 6, 2026Before open	Before open	+11.7%	+12.4%	+6.6%

IMVT closed higher after 4 of its last 4 reports.

All 4 reports, and IMVT's Quality Score going into each

Everyone reporting earnings next week

IMVT share count over time

20% more shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of IMVT outstanding, as filed
Shares outstanding	As of
206.6M	Aug 3, 2026
205.3M	May 14, 2026
203.5M	Feb 2, 2026
175.3M	Nov 3, 2025

Offerings, shelves, and splits of IMVT, from its filings
From its filings	Filed
Priced a sale of shares	Dec 12, 2025
Registered shares for a later sale (S-3ASR)	Nov 9, 2023

Insiders trading IMVT

IMVT insider trades

6 insiders sold $12.5M across 33 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellTiago Girao$188KChief Financial Officerat $28.50 on Oct 28, filed Oct 30

SellTiago GiraoChief Financial Officer$188Kat $28.50 on Oct 28, filed Oct 30

All 33 insider filings on IMVT from the last six months, for Pro members.Get in free →

All IMVT insider trades

IMVT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Eric VenkerChief Executive Officer · 4 trades
Tiago GiraoChief Financial Officer · 4 trades
Jay S. StoutChief Technology Officer · 16 trades
Melanie GloriaChief Operating Officer · 15 trades
Christopher Van TuylChief Legal Officer · 10 trades
Atul PandeDirector · 5 trades
Andrew J. FromkinDirector · 3 trades
Douglas J. HughesDirector · 1 trade

3 more officers and directors file at IMVT. Each page above names the rest.

See insider trades by person

Which ETFs hold IMVT?

In ETFs: IMVT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Immunovant

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

315 employeesDurham, NCimmunovant.com

IMVT's score card

Immunovant (IMVT): Quality Score -6, Poor, #235 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn IMVT's score around: 7 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 30Tiago Girao sold IMVT$188K at $28.50, filed Oct 30

Alerts are optional.

See IMVT's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: IMVT's Quality Score is -6 (Poor), #235 of 291 in Biotech. Insiders sold $12.5M in the last 6 months (Form 4).

Is IMVT a good stock to buy? What its Quality Score says

IMVT scores -6 today, which Breakaway calls Poor. It is #235 of 291 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 12% from Oct 5 to Oct 30 while the S&P 500 fell 3%. Cash lasts about 7 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IMVT's Quality Score?

IMVT scores -6 today, which Breakaway calls Poor (below zero). That is #235 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMVT's -6.

Are insiders buying IMVT?

6 insiders sold $12.5M across 33 filings in the last 6 months. No open-⁠market buys on record. The newest is Tiago Girao, Chief Financial Officer, who sold $188K on Oct 28. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.